

December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-003054-92/ Novartis Protocol ID CACZ885G2402

An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA)

Trial CACZ885G2402 was cancelled with no patient enrollment and as such, no results will be reported.